Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Regulatory T (Treg) cells mediate homeostatic peripheral tolerance by suppressing autoreactive T cells. Failure of host antitumor immunity may be caused by exaggerated suppression of tumor-associated antigen–reactive lymphocytes mediated by Treg cells; however, definitive evidence that Treg cells have an immunopathological role in human cancer is lacking. Here we show, in detailed studies of CD4+CD25+FOXP3+ Treg cells in 104 individuals affected with ovarian carcinoma, that human tumor Treg cells suppress tumor-specific T cell immunity and contribute to growth of human tumors in vivo. We also show that tumor Treg cells are associated with a high death hazard and reduced survival. Human Treg cells preferentially move to and accumulate in tumors and ascites, but rarely enter draining lymph nodes in later cancer stages. Tumor cells and microenvironmental macrophages produce the chemokine CCL22, which mediates trafficking of Treg cells to the tumor. This specific recruitment of Treg cells represents a mechanism by which tumors may foster immune privilege. Thus, blocking Treg cell migration or function may help to defeat human cancer.

[1]  M. Markman Optimizing primary chemotherapy in ovarian cancer. , 2003, Hematology/oncology clinics of North America.

[2]  J. Cyster,et al.  Chemokine Up-regulation and activated T cell attraction by maturing dendritic cells. , 1999, Science.

[3]  T. Curiel,et al.  Macrophage-Derived Dendritic Cells Have Strong Th1-Polarizing Potential Mediated by β-Chemokines Rather Than IL-121 , 2000, The Journal of Immunology.

[4]  Leonard C. Harrison,et al.  Regulatory lymphocytes: Antigen-induced regulatory T cells in autoimmunity , 2003, Nature Reviews Immunology.

[5]  M. Roncarolo,et al.  Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.

[6]  V. Cerundolo,et al.  Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC1 , 2001, The Journal of Immunology.

[7]  Meng-tse Wu,et al.  Cutting Edge: CCR4 Mediates Antigen-Primed T Cell Binding to Activated Dendritic Cells , 2001, The Journal of Immunology.

[8]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[9]  R. Lechler,et al.  Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. , 2001, Blood.

[10]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[11]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[12]  A. Iellem,et al.  Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells , 2001, The Journal of experimental medicine.

[13]  H. Waldmann,et al.  Regulatory T cells in transplantation tolerance. , 2005, Current topics in microbiology and immunology.

[14]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[15]  G. Schuler,et al.  Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.

[16]  G. Coukos,et al.  Regulatory CD 4 1 CD 25 1 T Cells in Tumors from Patients with Early-Stage Non-Small Cell Lung Cancer and Late-Stage Ovarian Cancer 1 , 2001 .

[17]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[18]  K. Wood,et al.  Regulatory lymphocytes: Regulatory T cells in transplantation tolerance , 2003, Nature Reviews Immunology.

[19]  Sayuri Yamazaki,et al.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance , 2001, Immunological reviews.

[20]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[21]  E. Shevach Regulatory T cells in autoimmmunity*. , 2000, Annual review of immunology.

[22]  K. Wood,et al.  Cutting Edge: CD4+CD25+ Alloantigen-Specific Immunoregulatory Cells That Can Prevent CD8+ T Cell-Mediated Graft Rejection: Implications for Anti-CD154 Immunotherapy1 , 2002, The Journal of Immunology.

[23]  G. Freeman,et al.  CD4+CD25+ regulatory cells from human peripheral blood express very high levels of CD25 ex vivo. , 2003, Novartis Foundation symposium.

[24]  Y. Rivière,et al.  A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. , 2001, Journal of immunological methods.

[25]  Clare Baecher-Allan,et al.  Inhibition of Human CD4+CD25+high Regulatory T Cell Function1 , 2002, The Journal of Immunology.

[26]  R. Noelle,et al.  Cd4+Cd25+ Immune Regulatory Cells Are Required for Induction of Tolerance to Alloantigen via Costimulatory Blockade , 2001, The Journal of experimental medicine.

[27]  Christopher Anderson,et al.  More questions than answers , 1991, Nature.

[28]  S. Riddell,et al.  Prospects for adoptive T cell therapy. , 1997, Current opinion in immunology.

[29]  G. Freeman,et al.  CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.

[30]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[31]  C. June,et al.  Cutting Edge: Regulatory T Cells from Lung Cancer Patients Directly Inhibit Autologous T Cell Proliferation1 , 2002, The Journal of Immunology.

[32]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[33]  K. Knutson,et al.  Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. , 2001, The Journal of clinical investigation.

[34]  F. Powrie,et al.  CD4(+) regulatory T cells. , 2001, Current opinion in immunology.

[35]  H. Schreiber,et al.  Immunodominance and tumor escape. , 2002, Seminars in cancer biology.

[36]  A. Harris,et al.  A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response1 , 2000, The Journal of Immunology.

[37]  E. Shevach,et al.  Cutting Edge: Control of CD8+ T Cell Activation by CD4+CD25+ Immunoregulatory Cells , 2001, The Journal of Immunology.

[38]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[39]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[40]  G. Ogg,et al.  Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.

[41]  T. Tüting,et al.  Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. , 2001, Cancer research.

[42]  J. Bach Regulatory lymphocytes: Regulatory T cells under scrutiny , 2003, Nature Reviews Immunology.

[43]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[44]  T. Curiel,et al.  Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells , 2001, Nature Medicine.

[45]  I. Bièche,et al.  Quantification of estrogen receptor α and β expression in sporadic breast cancer , 2001, Oncogene.

[46]  M. Maio,et al.  Melanoma immunotherapy: new dreams or solid hopes? , 1996, Immunology today.

[47]  J. Kirkwood,et al.  New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines , 1996, Melanoma research.

[48]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[49]  P. Galanaud,et al.  Quantification of cytokine gene expression by competitive PCR using a colorimetric assay. , 1995, European cytokine network.

[50]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[51]  D. Keskin,et al.  Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.

[52]  A. Rudensky,et al.  Foxp 3 programs the development and function of CD 4 + CD 25 + regulatory T cells , 2003 .